研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
城謙輔、小助川英之	薬剤性腎障害の病理	日本腎臓学会	日本腎臓学会誌	日本腎臓学会	東京	2012	54（7）958-971
城謙輔、中村保宏	オックスフォード分類が与えたインパクトとそのピットフォール		腎と透析	東京医学社	東京	2012	72（1）72-80
城謙輔、宮坂康宣	腎生検の電顕所見の読み方と診断（各論3）　メサンギウムと内皮細胞		Nephrology Frontier	メディカルレビュー社	大阪	2012	11（2）166-174
城謙輔、小野寺進，伊藤佳子，我妻登志子，鶴田里美，畠山篤	電顕像のartifactとその対処法		Nephrology Frontier	メディカルレビュー社	大阪	2012	11（4）367-371
武藤智，堀江重郎	V2受容体拮抗薬による多発性嚢胞腎治療		Annual Review 腎臓			2013	266-73
武藤智，堀江重郎	多発性嚢胞腎はCKDなのでしょうか？		CKD診療ガイド2012 Q&A	診断と治療社			
中西浩一，吉川徳茂	慢性糸球体腎炎　18章　腎・泌尿器・生殖器疾患	遠藤文夫	小児科診断・治療ガイド	中山書店		2012	673-9
中西浩一	遺伝性糸球体疾患	日本小児腎臓病学会	小児腎臓病学	診断と治療社		2012	210-4
中西浩一，吉川徳茂	多発性嚢胞腎（小児）	「腎と透析」編集委員会	腎疾患治療マニュアル2012-2013	東京医学社		2012	445-9
武藤智，堀江重郎	V.腎臓疾患　嚢胞性腎疾患		診断と治療増刊号　慢性疾患患者への薬物療法の鉄則	診断と治療社		2012	288-91
武藤智	血尿（特発性腎出血を含む）	今日に治療指針　私はこう治療している	Today' Therapy 2013	医学書院		2013	
武藤智，堀江重郎	原因疾患の管理　多発性嚢胞腎		Medical View Point			2013	34-3
横山仁、杉山斉、佐藤博	高齢者ネフローゼ症候群の現状と問題点	富野康日己	Annual Review 腎臓2013	中外医学社	東京	2013	179-186
横山仁，杉山斉，佐藤博，今井圓裕	2章　保存期慢性腎臓病（CKD）管理の意義と重要性 1.　保存期CKD管理の現状	衣笠えり子、小岩文彦、緒方浩顕、本田浩一	変革する透析医学	医学ジャーナル	大阪	2012	28-33

有村義宏(分担執筆)	免疫血清検査	中原一彦	ナースのための 検査値ガイド	総合医学社	東京	2012	189-193
有村義宏(分担執筆)	多発血管炎性肉芽腫症(ウェゲナー肉芽腫症)	足立 満 笠間 毅	アレルギー・リウマチ膠原病診療最新ガイドライン	総合医学社	東京	2012	200-202
有村義宏(分担執筆)	4.ANCA関連血管炎に伴う糸球体病変 Glomerular lesion in ANCA-associated vasculitis	『腎と透析』編集委員会	腎疾患治療マニュアル 2012-13	東京医学社	東京	2012	286-290
有村義宏(分担執筆)	MPAの厚生省の診断基準、病型分類	尾崎承一 槇野博史 松尾清一	ANCA関連血管炎の診療ガイドライン	厚生労働省難治性疾患克服研究事業	神奈川 岡山 名古屋	2012	16-18
有村義宏(分担執筆)	ANCA関連血管炎の成因	日本腎臓財団 「腎臓」編集委員会	腎臓	東京医学社	東京	2012	32-38
後藤 眞	4.次世代シーケンサ	富野康日己 柏原直樹 成田一衛	Annual Review腎臓	中外医学社	東京	2013	95-100
金子佳賢	1.糖鎖不全IgAに対する新規受容体とIgA腎症発症機序	富野康日己 柏原直樹 成田一衛	Annual Review腎臓	中外医学社	東京	2012	36-42
秋山真一、今井圓裕	3.膜性腎症の抗PLA2R抗体測定の現状と展望		医薬ジャーナル	医薬ジャーナル社	大阪	2012	71-76

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hirano K, Kawamura T, Tsuboi N, etal.	The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy.	Clin Exp Nephrol.	In press		2012
Tsuboi N, Koike K, Hirano K, et al.	Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy.	Clin Exp Nephrol.	In press		2012
Tsuboi N, Utsunomiya Y, Koike K, et al.	Factors related to the glomerular size in renal biopsies of chronic kidney disease patients.	Clin Nephrol.	In press		2012
Kawamura T, Joh K, Okonogi H, Koike K, et al.	A histological classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease.	J Nephrol.			2012
Kurosu A, Oka N, Hamaguchi T, Yoshikawa N, Joh K.	Infantile immunoglobulin A nephropathy showing features of membranoproliferative glomerulonephritis.	Tohoku J Exp Med.	228 (3)	253-8	2012
Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, Kobayashi M, Koyama A, Sugiyama H, Nitta K, Wada T, Muso E, Arimura Y, Makino H, Matsuo S	ANCA-associated systemic vasculitis in Japan: Clinical features and prognostic changes	Clin Exp Nephrol	16	580-588	2012
Kawamura T, Usui J, Kaseda K, Takada K, Ebihara I, Ishizu T, Iitsuka T, Sakai K, Takemura K, Kobayashi M, Koyama A, Kanemoto K, Sumazaki R, Uesugi N, Noguchi M, Nagata M, Suka M, Yamagata K	Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan	Clin Exp Nephrol			In press
Yamagata K, Usui J, Sugiyama H, Nitta K, Wada T, Muso E, Arimura Y, Koyama A, Makino H, Matsuo S	Clinical findings on ANCA-associated renal vasculitis from the Japan RPGN registry obtained via a questionnaire survey	Clin Exp Nephrol			In press

Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, Tsuruya K, Kiyomoto H, Iida H, Sasaki T, Higuchi M, Hattori M, Oka K, Kagami S, Kawamura T, Takeda T, Hataya H, Fukasawa Y, Fukatsu A, Morozumi K, Yoshikawa N, Shimizu A, Kitamura H, Yuzawa Y, Matsuo S, Kiyohara Y, Joh K, Nagata M, Taguchi T, Makino H	Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010	Clin Exp Nephrol				In press
臼井丈一，山縣邦弘	急速進行性腎炎症候群	知っておきたい内科症候群. 内科増大号	109	1399-1401		2012
臼井丈一，山縣邦弘	半月体形成性糸球体腎炎	腎疾患治療マニュアル 2012-13. 腎と透析増刊号	72	258-261		2012
武藤　智，堀江重郎	多発性囊胞腎の新たな治療	医薬ジャーナル	48	89-92		2013
島友子，中西浩一，吉川徳茂	【小児の診療手技100】腎生検	小児科診療	75	286-90		2012
中西浩一，吉川徳茂	遺伝性腎炎（Alport症候群） 小児疾患の診断治療基準 第4版	小児内科	44	630-1		2012
中西浩一，吉川徳茂	遺伝子診断の臨床応用-ネフローゼ症候群	小児内科　クローズアップ腎泌尿器	44	210-5		2012
中西浩一，吉川徳茂，服部元史	常染色体劣性多発性囊胞腎-疫学と臨床. 特集：多発性囊胞腎	腎臓	34	194-200		2012
武藤　智，堀江重郎	特集　多発性囊胞腎　囊胞の増大抑制と腎機能障害の抑制	腎臓	34			2012
中西浩一，吉川徳茂	繊毛病（Ciliopathy）	日本小児腎臓病学会雑誌	25	127-31		2012
中西浩一，吉川徳茂	ARPKDの基礎と臨床-最新の知見 特集：多発性囊胞腎-最新の知見と今後の課題	日本腎臓学会誌	54	534-7		2012
堀江重郎，武藤　智	特集：多発性囊胞腎—最新の知見と今後の課題　ADPKDにおける腎容積と腎機能	日本腎臓学会誌	54	501-5		2012
武藤　智	特集：多発性囊胞腎—最新の知見と今後の課題　肝囊胞—QOLへの影響とその対策	日本腎臓学会誌	54	512-6		2012
戸川寛子，中西浩一，吉川徳茂	髄質囊胞腎. 腎臓症候群（第2版）—その他の腎臓疾患を含めて	別冊日本臨床 新領域別症候群シリーズ	17	600-2		2012

H. Yokoyama, T. Taguchi, H. Sugiyama, H. Sato	: Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR)	Clin. Exp. Nephrol	16:	557-563	2012
H. Yokoyama, H. Sugiyama, H. Sato, T. Taguchi, M. Nagata, S. Matsuo, H. Makino, T. Watanabe, T. Saito, Y. Kiyohara, S. Nishi, H. Iida, K. Morozumi, A. Fukatsu, T. Sasaki, K. Tsuruya, Y. Kohda, M. Higuchi, H. Kiyomoto, S. Goto, M. Hattori, H. Hataya, S. Kagami, N. Yoshikawa, Y. Fukasawa, Y. Ueda, H. Kitamura, A. Shimizu, K. Oka, N. Nakagawa et al 19	Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR)	Clin. Exp. Nephrol.	16	903-920	2012
横山　仁	特集 ネフローゼ症候群治療の最前線 腎臓病総合レジストリーからみたネフローゼ症候群の疫学	腎と透析	72	779-783	2012
横山　仁	特集 CKD キャンペーンの成果と今後の CKD・透析医療 Ⅱ CKD 疫学研究の進捗状況と成果 (1)日本腎臓学会 CKD 総合レジストリーシステムの構築	臨透析	28	1323-1330	2012
Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, Kobayashi M, Koyama A, Sugiyama H, Nitta K, Wada T, Muso E, Arimura Y, Makino H, Matsuo S.	ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes.	Clin Exp Nephrol	16	580-588	2012
有村義宏	顕微鏡的多発血管炎	日本医師会雑誌	140(11)	2305-2309	2012
有村義宏	壊死性糸球体腎炎. 腎臓症候群（第2版）—その他の腎臓疾患を含めて—.	別冊　日本臨床　新領域別症候群シリーズ	17	65-69	2012
有村義宏	ANCA 関連腎炎. 腎臓症候群（第2版）—その他の腎臓疾患を含めて—	別冊　日本臨床　新領域別症候群シリーズ	18	468-473	2012
Wada T, Hara A, Arimura Y, Sada K, Makino H, and the Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan.	Risk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis.	The Journal of Rheumatology	39(3)	545-551	2012
有村義宏	ANCA 関連血管炎の成因. 特集：免疫異常と腎障害	腎臓	35(1)	32-38	2012

有村義宏	ANCA 関連血管炎に伴う糸球体病変—Glomerular lesion in ANCA-associated vasculitis—.治療各論　続発性腎疾患	腎と透析	72 増刊号	286-290	2012
有村義宏,吉澤　亮,清水英樹	血管炎研究の進歩-側頭動脈炎，多発性動脈炎-.	心臓	44 (9)	1110-1115	2012
有村義宏	KDIGO:糸球体腎炎診療ガイドライン.	腎と透析	73 (4)	591-594	2012
Ogasawara S, et al.	Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes.	Diabetes Care	35	1112-1118	2012
Kaneko Y, et al.	Integrin alpha1/beta1 and alpha2/beta1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy	Int Immunol	24	219-232	2012
Kiryluk K, et al.	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis	PLoS Genet	8	e1002765	2012
Takeyama A, et al.	Megalin is downregulated via LPS-TNF-alpha-ERK1/2 signaling pathway in proximal tubule cells.	Biochem Biophys Res Com	407	108-112	2012
Wakasugi M, et al.	Differences in the local and national prevalences of chronic kidney disease based on annual health check program data	Clinl Exp Nephrol	16	749-754	2012
Wakasugi M , et al.	Use of Japanese Society for Dialysis Therapy dialysis tables to compare the local and national incidence of dialysis.	Ther Aphe Dial	16	63-67	2012
Yoshita K et al.	Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis	Nephrol Dial Transpl	27	2755-2761	2012
Wang X, et al.	Quantitative Histological Analysis of SM22alpha (Transgelin) in an Adriamycin-Induced Focal Segmental Glomerulosclerosis Model	Nephron Exp Nephrol	120	E1-11	2012

Nozawa Y, et al.	The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I (2) analog on the progression of sclerotic glomerulonephritis in rats.	Clin Exp Nephrol	16	221-230	2012
Sato A, Piao H, Nozawa Y, Morioka T, Kawachi H, Oite T	Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.	Clinical and Experimental Nephrology	16	539-548	2012
Toyama K, Morisaki H, Cheng J, Kawachi H, Shimizu F, Ikawa M, Okabe M, Morisaki T.	Proteinuria in AMPD2-deficient mice.	Genes to Cells	17	28-38	2012
Ramadan R, Faour D, Awad H, Khateeb E, Cohen R, Yahia A, Torgovicky R, Cohen R, LazariD, Kawachi H, Abassi Z.	Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrom	Nephrology Dialysis Transplantation	27	2231-2241	2012
Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K, Kawachi H, Watanabe K	Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats	The Journal of Nutritional Biochemistry			In press
Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, Suzuki K, Kawachi H, Watanabe K.	Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway.	Mol Nutr Food Res.			In press
Mishima K, Maeshima A, Miya M, Sakurai N, Ikeuchi H, Hiromura K, Nojima Y.	Involvement of N-type Ca2+ Channels in Fibrotic Process of the Kidney in Rats	Am J Physiol Renal Physiol			In press
Kimura T, Takabatake T, Takahashi A, Isaka Y.	Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy	Cancer Res.	73	3-7	2013
Kaimori JY, Ichimaru N, Isaka Y, Hashimoto F, Fu X, Hashimura Y, Kaito H, Iijima K, Kyo M, Namba T, Obi Y, Hatanaka M, Matsui I, Takabatake Y, Okumi M, Yazawa K, Nonomura N, Rakugi H, Takahara S	Renal transplantations from their parents to siblings with autosomal recessive Alport syndrome caused by a rearrangement in an intronic antisense Alu element in the COL4A3 gene led to different outcomes	Clin Exp Nephrol. Case Reports			In press

Mishima K, Maeshima A, Miya M, Sakurai N, Ikeuchi H, Hiromura K, Nojima Y.	Involvement of N-type Ca2+ Channels in Fibrotic Process of the Kidney in Rats	Am J Physiol Renal Physiol			In press
武曾 惠理, 斉藤 喬雄	難治性ネフローゼ症候群に対するLDLアフェレシスの前向きコホート研究(POLARIS調査)報告　中長期予後の解析	Therapeutic Research	33(8)	1220-1222	2012
Muso E, Endo T, Itabashi M, Kakita H, Iwasaki Y, Tateishi Y, Komiya T, Ihara T, Yumura W, Sugiyama T, Joh K, Suzuki K.	Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts.	Clin Exp Nephrol			In press

SPECIAL REPORT

Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010

Hitoshi Sugiyama · Hitoshi Yokoyama · Hiroshi Sato · Takao Saito · Yukimasa Kohda · Shinichi Nishi ·
Kazuhiko Tsuruya · Hideyasu Kiyomoto · Hiroyuki Iida · Tamaki Sasaki · Makoto Higuchi ·
Motoshi Hattori · Kazumasa Oka · Shoji Kagami · Tetsuya Kawamura · Tetsuro Takeda · Hiroshi Hataya ·
Yuichiro Fukasawa · Atsushi Fukatsu · Kunio Morozumi · Norishige Yoshikawa · Akira Shimizu ·
Hiroshi Kitamura · Yukio Yuzawa · Seiichi Matsuo · Yutaka Kiyohara · Kensuke Joh · Michio Nagata ·
Takashi Taguchi · Hirofumi Makino · Committee for Standardization of Renal Pathological Diagnosis
and Committee for Kidney Disease Registry, Japanese Society of Nephrology, Japan

Abstract The Japan Renal Biopsy Registry (J-RBR) was started in 2007 and the Japan Kidney Disease Registry (J-KDR) was then started in 2009 by the Committee for Standardization of Renal Pathological Diagnosis and the Committee for the Kidney Disease Registry of the Japanese Society of Nephrology. The purpose of this report is to describe and summarize the registered data from 2009 and 2010. For the J-KDR, data were collected from 4,016 cases, including 3,336 (83.1 %) by the J-RBR and 680 (16.9 %) other cases from 59 centers in 2009, and from 4,681 cases including 4,106 J-RBR cases (87.7 %) and 575 other cases (12.3 %) from 94 centers in 2010, including the affiliate hospitals. In the J-RBR, 3,165 native kidneys (94.9 %) and 171 renal grafts (5.1 %) and 3,869 native kidneys (94.2 %) and 237 renal grafts (5.8 %) were registered in 2009 and 2010, respectively. Patients younger than 20 years of age comprised 12.1 % of the registered cases, and those 65 years and over comprised 24.5 % of the cases with native kidneys in 2009 and 2010. The most common clinical diagnosis was chronic

H. Sugiyama · H. Makino
Department of Medicine and Clinical Science, Okayama
University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences, Okayama, Japan

H. Yokoyama (✉)
Division of Nephrology, Kanazawa Medical University School
of Medicine, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
e-mail: h-yoko@kanazawa-med.ac.jp

H. Sato
Division of Nephrology, Tohoku University Graduate School
of Medicine, Sendai, Japan

T. Saito
Division of Nephrology and Rheumatology, Department
of Internal Medicine, Fukuoka University School of Medicine,
Fukuoka, Japan

Y. Kohda
Department of Nephrology, Faculty of Life Sciences,
Kumamoto University, Kumamoto, Japan

Present Address:
Y. Kohda
Hikarinomori Clinic, Kumamoto, Japan

S. Nishi
Division of Nephrology and Kidney Center, Kobe University
School of Medicine, Kobe, Japan

K. Tsuruya
Department of Integrated Therapy for Chronic Kidney Disease,
Graduate School of Medical Sciences, Kyushu University,
Fukuoka, Japan

H. Kiyomoto
Division of Integrated Nephrology and Telemedicine,
Department of Community Medical Supports, Tohoku Medical
Megabank Organization, Tohoku University, Sendai, Japan

H. Iida
Department of Internal Medicine, Toyama Prefectural Central
Hospital, Toyama, Japan

T. Sasaki
Division of Nephrology and Hypertension, Department
of Internal Medicine, Kawasaki Medical School, Kurashiki,
Japan

M. Higuchi
Division of Nephrology, Department of Internal Medicine,
Shinshu University School of Medicine, Matsumoto, Japan

🖄 Springer

nephritic syndrome (55.4 % and 50.0 % in 2009 and 2010, respectively), followed by nephrotic syndrome (22.4 % and 27.0 %); the most frequent pathological diagnosis as classified by the pathogenesis was IgA nephropathy (31.6 % and 30.4 %), followed by primary glomerular diseases (except IgA nephropathy) (27.2 % and 28.1 %). Among the primary glomerular diseases (except IgA nephropathy) in the patients with nephrotic syndrome, membranous nephropathy was the most common histopathology in 2009 (40.3 %) and minor glomerular abnormalities (50.0 %) were the most common in 2010 in native kidneys in the J-RBR. Five new secondary and longitudinal research studies by the J-KDR were started in 2009 and one was started in 2010.

Keywords Native kidney biopsy · Primary glomerulonephritis · IgA nephropathy · Membranous nephropathy · Renal grafts · National registry

Introduction

The Japanese Society of Nephrology (JSN) established the Japan Renal Biopsy Registry (J-RBR) in 2007, and it conducted analyses for 2007 and 2008 [1]. In 2009, the JSN started the Japan Kidney Disease Registry (J-KDR) to record clinically-diagnosed cases in addition to the J-RBR. Participation in the J-KDR, including the J-RBR, was

requested from appointed clinical training hospitals of the JSN and the Japanese Society for Dialysis Therapy in an attempt to extend the registry nationwide. In this report, the detailed data of the J-RBR and the frequencies of the different clinical diagnoses in the J-KDR registered from January to December of 2009 and 2010 are summarized.

Subjects and methods

Registry system and patients

This report includes the data from patients included in the J-RBR and J-KDR (J-RBR/J-KDR), registered prospectively from January 2009 to December 2010. The patients' data, including age, gender, laboratory data, and the clinical and pathological diagnoses, were recorded at each institution and registered on the web page of the J-RBR/J-KDR utilizing the Internet Data and Information Center for Medical Research (INDICE) system of the University Hospital Medical Information Network (UMIN), as described previously [1]. The ethics committee of the JSN and that of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences comprehensively approved the study, and a local committee of participating centers and their affiliate hospitals individually approved the study. Written informed consent was

M. Hattori
Department of Pediatric Nephrology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan

K. Oka
Department of Pathology, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan

S. Kagami
Department of Pediatrics, The Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan

T. Kawamura
Department of Medicine, Division of Kidney and Hypertension, Jikei University School of Medicine, Tokyo, Japan

T. Takeda
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Present Address:
T. Takeda
Department of Nephrology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

H. Hataya
Department of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

Y. Fukasawa
Department of Pathology, KKR Sapporo Medical Center, Sapporo, Japan

A. Fukatsu
Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Present Address:
A. Fukatsu
Department of Nephrology, Yachiyo Hospital, Anjo, Japan

K. Morozumi
Kidney Center, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

N. Yoshikawa
Department of Pediatrics, Wakayama Medical University, School of Medicine, Wakayama, Japan

A. Shimizu
Department of Pathology, Nippon Medical School, Tokyo, Japan

H. Kitamura
Department of Pathology, Clinical Research Center, National Hospital Organization Chiba East National Hospital, Chiba, Japan

obtained from the patients at the time of biopsy or at the time they were registered to participate in the study. The J-RBR/J-KDR is registered in the Clinical Trial Registry of UMIN (Registered Number UMIN000000618).

Clinical or renal histopathological diagnosis and laboratory data

Three classifications, including the clinical diagnosis, histological diagnosis based on the pathogenesis, and histological diagnosis based on a histopathological examination, were made for each case included in the J-RBR, as described previously [1]. Of these classifications, the clinical diagnosis alone was selected for the J-KDR. The definition of each diagnosis was based on the clinical syndromes and renal histopathology, as described previously [2]. IgA nephropathy (IgAN) (Berger disease) was separated from primary glomerular diseases on the basis of basic glomerular alterations in the classification of glomerular diseases by the World Health Organization [2]. In 2010, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura (HUS/TTP), congenital anomalies of the kidney and urinary tract (CAKUT) and polycystic kidney disease (PKD) were added to the classification of the clinical diagnosis on the case record (Table S1). The clinical data, including the results of the urinalysis, daily proteinuria, serum creatinine concentrations, total protein,

Y. Yuzawa
Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan

S. Matsuo
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Y. Kiyohara
Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

K. Joh
Division of Pathology, Sendai Shakai Hoken Hospital, Sendai, Japan

M. Nagata
Molecular Pathology, Biomolecular and Integrated Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

T. Taguchi
Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

Present Address:
T. Taguchi (✉)
Department of Pathology, Nagasaki Municipal Hospital, Nagasaki, Japan
e-mail: taguchi@nagasaki-u.ac.jp

albumin, and the total cholesterol values, were always recorded, while the systolic and diastolic blood pressure, prescription use of anti-hypertensive agents, hemoglobin A1c, and presence of diabetes mellitus were optionally recorded. The estimated glomerular filtration rate was calculated as described previously [3]. The frequency of the diseases are here described in general, but the clinical data were also analyzed separately for cases of IgAN, which is the most common renal disease in Japan [1, 4, 5].

Statistical analyses

Data are expressed as the mean ± SD for continuous parametric data, medians and interquartile ranges for continuous non-parametric data, and frequencies for categorical data. The statistical analyses were performed using the JMP software program, version 8 (SAS Institute Inc., Cary, NC, USA).

Results

Baseline characteristics of the J-RBR/J-KDR participants in 2009 and 2010

The numbers of participating facilities and registered renal biopsies or cases without renal biopsies in the registry in 2009 and 2010 are shown in Table 1. The J-KDR was started in 2009 and the number of participating facilities increased by 34 compared to 2008, reaching a total of 57 facilities in the J-RBR and 59 facilities in the J-KDR. The number of total renal biopsies increased to 3,336 in 2009, which was 1,754 more biopsies than in the previous year [1], and in 2010 it further increased to 4,106 in the J-RBR. The number of other cases (not in the J-RBR), which corresponds to the cases without renal biopsies but diagnosed by clinical findings, was 680 and 575 in 2009 and 2010, respectively. The average age of this cohort was more than 10 years higher than that of the J-RBR in each year (Table 1).

The number of native kidney biopsies increased; however, that of renal graft biopsies registered in 2009 slightly decreased compared to 2008 (Table 2). The distribution of age ranges showed a peak distribution in the seventh decade in both genders for native kidneys (Table 3). Patients younger than 20 years of age comprised 12.1 % and 10.3 % of the cases, and those 65 years of age and over comprised 24.5 % and 4.7 % of the native kidney and renal grafts, respectively, during the 2-year period (2009 and 2010). In the patients who underwent renal grafts, both the average age and the peak distribution of age ranges were younger than those of patients who underwent native kidney biopsies (Tables 2, 3).

Table 1 The number of participated renal centers and registered renal biopsies or other cases without renal biopsies in J-RBR/J-KDR 2009 and 2010

	2009 J-KDR			2010 J-KDR		
	J-RBR	Other cases[a]	Total	J-RBR	Other cases[a]	Total
Renal centers (n)[b]	57[c]	–	59	83	–	94
Total biopsies or cases (n)	3,336[d] (83.1 %)	680 (16.9 %)	4,016 (100.0 %)	4,106 (87.7 %)	575 (12.3 %)	4,681 (100.0 %)
Average age (years)	46.7 ± 19.9	58.1 ± 17.8	48.7 ± 20.0	46.7 ± 20.6	56.8 ± 21.1	47.9 ± 20.9
Male (n)	1,787 (53.6 %)	418 (61.5 %)	2,205 (54.9 %)	2,183 (53.2 %)	335[e] (58.3 %)	2,518[e] (53.8 %)
Female (n)	1,549 (46.4 %)	262 (38.5 %)	1,811 (45.1 %)	1,923 (46.8 %)	238[e] (41.4 %)	2,161[e] (46.2 %)

J-RBR Japan Renal Biopsy Registry, *J-KDR* Japan Kidney Disease Registry

Note that J-RBR started in 2007 and J-KDR started in 2009

[a] Other cases include patients diagnosed by clinical findings without renal biopsies

[b] The number represents principal institutions having affiliate hospitals. All of the participated institutions and hospitals in the J-RBR and J-KDR in 2009 and 2010 are shown in the "Appendix". The number of renal centers in total is based on the registration of cases without renal biopsies but diagnosed by clinical findings in addition to that of data with renal biopsy in J-RBR

[c] Increase of 34 when compared to the number in J-RBR 2008

[d] Increase of 1,754 when compared to the number in J-RBR 2008

[e] No registered data for gender in 2 cases

The frequency of clinical diagnoses in the J-RBR

Three classifications, the clinical diagnosis, histological diagnosis based on the pathogenesis, and the histological diagnosis based on a histopathological examination, were included in the J-RBR database, while the clinical diagnosis alone was registered for the other cases. In the J-RBR, a clinical diagnosis of chronic nephritic syndrome was the most common, followed by nephrotic syndrome, in both total biopsies and native kidneys in 2009 and 2010, which was similar to the findings in 2007 and 2008 (Table 4) [1]. In native kidneys, more than half of the cases that were registered had chronic nephritic syndrome. The age distribution according to the classification of clinical diagnoses in native kidneys in the J-RBR in 2009 and 2010 was analyzed, and cases with rapidly progressive nephritic syndrome exhibited the highest mean age while cases with inherited renal diseases showed the youngest mean age (Table 5).

The frequency of pathological diagnoses in the J-RBR

The pathological diagnoses were classified based on the pathogenesis (Table 6) and histopathology (Table 7). In the classification of the pathogenesis, IgAN was diagnosed most frequently (31.6 %), followed by primary glomerular disease other than IgAN (27.2 %) in native kidneys in both 2009 and 2010 (Table 6). Similar frequencies of IgAN, primary glomerular disease other than IgAN and diabetic nephropathy were observed in the combined data for 2007 and 2008 [1]. In the pathological diagnosis classified based on the histopathology in native kidney biopsies, mesangial

Table 2 The number of registered renal biopsies in J-RBR 2009 and 2010

Years	2009	2010	Total
Native kidneys, n (%)	3,165[a] (94.9)	3,869 (94.2)	7,034 (94.5)
Average age (years)	47.0 ± 20.1	47.1 ± 20.8	47.1 ± 20.5
Median age (years)	50 (30–64)	49 (31–65)	49 (30–64)
Male, n (%)	1,671 (52.8)	2,035 (52.6)	3,706 (52.7)
Female, n (%)	1,494 (47.2)	1,834 (47.4)	3,328 (47.3)
Renal grafts, n (%)	171[b] (5.1)	237 (5.8)	408 (5.5)
Average age (years)	40.9 ± 15.0	41.3 ± 15.4	41.1 ± 15.2
Median age (years)	43 (31–52)	41 (33–54)	42 (32–53)
Male, n (%)	116 (67.8)	148 (62.4)	264 (64.7)
Female, n (%)	55 (32.2)	89 (37.6)	144 (35.3)

[a] Increase of 1,765 when compared to the number in J-RBR 2008

[b] Decrease of 11 when compared to the number in J-RBR 2008

proliferative glomerulonephritis was the most frequently observed disease, representing 42.5 % and 35.8 % of the cases in 2009 and 2010 (Table 7).

Primary glomerular disease (except IgAN) and nephrotic syndrome in the J-RBR

In the cohort of primary glomerular diseases (except IgA nephropathy) as classified based on the pathogenesis, membranous nephropathy (MN) was predominant in 2009, followed by minor glomerular abnormalities, while minor glomerular abnormalities were the most common diagnosis in 2010, followed by MN (Table 8).

Table 3 Distribution of age ranges and gender in J-RBR 2009 and 2010

Age (years)	2009									2010								
	Total biopsies (n = 3,336)			Native kidneys (n = 3,165)			Renal grafts (n = 171)			Total biopsies (n = 4,106)			Native kidneys (n = 3,869)			Renal grafts (n = 237)		
	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
0–9	60	33	27	57	32	25	3	1	2	121	94	27	136	87	49	7	7	0
10–19	318	169	149	304	160	144	14	9	5	352	203	149	354	193	161	18	10	8
20–29	413	194	219	392	180	212	21	14	7	406	187	219	429	167	262	22	20	2
30–39	476	221	255	438	193	245	38	28	10	533	278	255	549	248	301	62	30	32
40–49	434	222	212	391	197	194	43	25	18	489	277	212	489	251	238	50	26	24
50–59	545	317	228	509	291	218	36	26	10	575	347	228	541	311	230	49	36	13
60–69	645	382	263	631	371	260	14	11	3	733	470	263	756	452	304	28	18	10
70–79	372	213	159	370	211	159	2	2	0	437	278	159	515	277	238	1	1	0
80+	73	36	37	73	36	37	0	0	0	86	49	37	100	49	51	0	0	0
Total	3,336	1,787	1,549	3,165	1,671	1,494	171	116	55	3,732	2,183	1,549	3,869	2,035	1,834	237	148	89
Under 20 (%)	11.3	11.3	11.4	11.4	11.5	11.3	9.9	8.6	12.7	12.5	13.6	11.4	12.7	13.8	11.5	10.5	11.5	9.0
65 and over (%)	22.4	23.9	20.1	23.4	25.3	21.3	4.7	4.3	5.5	24.2	25.4	20.7	25.4	26.9	23.7	4.6	5.4	3.4

Age (years)	Total								
	Total biopsies (n = 7,442)			Native kidneys (n = 7,034)			Renal grafts (n = 408)		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
0–9	203	127	76	193	119	74	10	8	2
10–19	690	372	318	658	353	305	32	19	13
20–29	864	381	483	821	347	474	43	34	9
30–39	1,087	499	588	987	441	546	100	58	42
40–49	973	499	474	880	448	432	93	51	42
50–59	1,135	664	471	1,050	602	448	85	62	23
60–69	1,429	852	577	1,387	823	564	42	29	13
70–79	888	491	397	885	488	397	3	3	0
80+	173	85	88	173	85	88	0	0	0
Total	7,442	3,970	3,472	7,034	3,706	3,328	408	264	144
Under 20 (%)	12.0	12.6	11.3	12.1	12.7	11.4	10.3	10.2	10.4
65 and over (%)	23.4	24.7	21.8	24.5	26.1	22.6	4.7	4.9	4.2

Table 4 The frequency of classification of clinical diagnoses in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies (n = 3,336)		Native kidneys (n = 3,165)	Total biopsies (n = 4,106)		Native kidneys (n = 3,869)	Total biopsies (n = 7,442)		Native kidneys (n = 7,034)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
Chronic nephritic syndrome	1,759	52.7	55.4	1,944	47.3	50.0	3,703	49.8	52.5
Nephrotic syndrome	711	21.3	22.4	1,044	25.4	27.0	1,755	23.6	24.9
Rapidly progressive nephritic syndrome	200	6.0	6.3	292	7.1	7.5	492	6.6	7.0
Renal transplantation	160	4.8	–	227	5.5	–	387	5.2	–
Renal disorder with collagen disease or vasculitis	116	3.5	3.7	144	3.5	3.7	260	3.5	3.7
Recurrent or persistent hematuria	97	2.9	3.0	111	2.7	2.9	208	2.8	2.9
Renal disorder with metabolic disease	63	1.9	2.0	61	1.5	1.6	124	1.7	1.8
Acute nephritic syndrome	54	1.6	1.6	58	1.4	1.5	112	1.5	1.6
Hypertensive nephropathy	39	1.2	1.2	54	1.3	1.4	93	1.3	1.3
Acute renal failure	36	1.1	1.1	35	0.9	0.9	71	1.0	1.0
Drug-induced nephropathy	13	0.4	0.4	26	0.6	0.6	39	0.5	0.5
Inherited renal disease	6	0.2	0.2	15	0.4	0.4	21	0.3	0.3
HUS/TTP	–	–	–	3	0.1	0.1	3	0.0	0.0
Others	82	2.5	2.6	92	2.2	2.4	174	2.4	2.5
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

In the patients with nephrotic syndrome as classified by the clinical diagnosis, primary glomerular disease other than IgAN was the predominant diagnosis in both 2009 and 2010, followed by diabetic nephropathy, which was the same order as in 2007 and 2008 (Table 9). Among the patients with primary glomerular diseases (except IgA nephropathy) who had nephrotic syndrome, MN was dominant, followed by minor glomerular abnormalities, viz., minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS), and membranoproliferative glomerulonephritis (MPGN) (types I and III) in 2009. In 2010, minor glomerular abnormalities were the leading diagnosis, followed by MN, FSGS, and MPGN (types I and III) (Table 10).

Clinical diagnosis of membranous nephropathy, minor glomerular abnormalities, and focal segmental glomerulosclerosis in patients with primary glomerular diseases (except IgA nephropathy) in the J-RBR

A subanalysis of the subjects with a clinical diagnosis of MN, minor glomerular abnormalities, and FSGS who had primary glomerular diseases (except IgA nephropathy) was also performed, since these were the most common forms of such diseases. Nephrotic syndrome was the most common clinical diagnosis in cases with primary MN and

primary minor glomerular abnormalities (MCNS) (Tables 11, 12), whereas chronic nephritic syndrome and nephrotic syndrome were the most common in cases with primary FSGS in 2009 and 2010, respectively (Table 13).

Subanalysis of cases of IgA nephropathy in the J-RBR

The profile, distribution of age ranges, classification of the clinical diagnosis, and the pathological diagnosis of IgAN, the most common glomerulonephritis reported in the J-RBR, were further analyzed (Tables 14, 15, 16, 17, 18, S2, S3). The average age of the overall subjects was in the fourth decade. There were no differences in the proportion of patients based on gender, but the age was significantly higher in males than in females in 2009 (Table 14). In terms of the distribution of age ranges, the peak distribution was in the twenties individually in both genders and in the overall cases in 2009, while it was in the thirties in both genders and overall in 2010, as well as in the combined data from 2009 and 2010 (Table 15). Patients younger than 20 years of age comprised 14.4 % of the cases and those 65 years and over comprised 7.9 % of the cases in the combined data from 2009 and 2010 (Table 15). The majority of the clinical and pathological diagnoses were chronic nephritic syndrome (Table 16) and mesangial proliferative glomerulonephritis (Table 17), respectively,

Table 5 The age distribution of classification of clinical diagnoses in native kidneys in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Chronic nephritic syndrome	44.4 ± 18.8	41.2 ± 17.8	42.8 ± 18.4	43.5 ± 19.3	41.0 ± 18.2	42.2 ± 18.8	43.9 ± 19.1	41.0 ± 18.0	42.5 ± 18.6
Nephrotic syndrome	52.6 ± 21.6	54.7 ± 21.1	53.5 ± 21.4	49.5 ± 23.4	50.9 ± 22.6	50.1 ± 23.0	50.8 ± 22.7	52.5 ± 22.0	51.5 ± 22.4
Rapidly progressive nephritic syndrome	64.5 ± 13.0	61.2 ± 17.4	63.0 ± 15.1	65.4 ± 11.5	65.3 ± 15.3	65.4 ± 13.3	65.1 ± 12.1	63.6 ± 16.3	64.4 ± 14.1
Renal disorder with collagen disease or vasculitis	48.0 ± 21.5	46.2 ± 20.1	46.7 ± 20.4	54.3 ± 19.5	46.3 ± 19.6	48.7 ± 19.9	51.6 ± 20.5	46.2 ± 19.8	47.8 ± 20.1
Recurrent or persistent hematuria	33.4 ± 17.4	33.8 ± 16.9	33.6 ± 17.0	49.5 ± 19.0	38.0 ± 17.1	42.6 ± 18.6	41.8 ± 19.9	36.1 ± 17.0	38.4 ± 18.4
Renal disorder with metabolic disease	56.9 ± 12.3	57.9 ± 8.9	57.2 ± 11.5	56.8 ± 14.8	54.8 ± 14.1	56.2 ± 14.5	56.9 ± 13.5	56.2 ± 11.9	56.7 ± 13.0
Acute nephritic syndrome	42.8 ± 19.2	36.0 ± 22.5	39.9 ± 20.7	49.6 ± 17.5	46.6 ± 21.1	48.1 ± 19.3	46.1 ± 18.5	42.0 ± 22.1	44.2 ± 20.3
Hypertensive nephropathy	56.2 ± 13.5	51.0 ± 15.3	55.2 ± 13.8	54.5 ± 15.9	54.7 ± 17.0	54.6 ± 16.0	55.3 ± 14.8	53.3 ± 16.1	54.8 ± 15.1
Acute renal failure	56.0 ± 19.3	56.4 ± 26.2	56.1 ± 21.2	55.2 ± 17.6	58.0 ± 20.6	56.0 ± 18.2	55.6 ± 18.3	57.1 ± 23.1	56.0 ± 19.7
Drug-induced nephropathy	53.6 ± 11.9	35.2 ± 21.6	45.1 ± 18.9	47.3 ± 20.0	60.4 ± 17.6	51.5 ± 19.9	49.1 ± 18.0	49.6 ± 22.7	49.3 ± 19.5
Inherited renal disease	25.0 ± 23.8	40.7 ± 24.1	32.8 ± 23.1	15.0 ± 17.1	24.3 ± 25.3	19.3 ± 21.1	17.7 ± 18.5	29.2 ± 24.9	23.2 ± 22.0
HUS/TTP	–	–	–	10, 69	49	42.6 ± 30.0	10, 69	49	42.6 ± 30.0
Others	50.6 ± 18.2	48.4 ± 19.5	49.6 ± 18.7	48.6 ± 20.9	53.3 ± 18.1	50.5 ± 19.8	49.4 ± 19.6	50.9 ± 18.9	50.0 ± 19.2
Total	48.4 ± 20.0	45.5 ± 20.0	47.0 ± 20.1	48.2 ± 21.0	46.0 ± 20.5	47.1 ± 20.8	48.3 ± 20.6	45.8 ± 20.3	47.1 ± 20.5

in 2009 and 2010. The distribution of chronic kidney disease (CKD) stages, degree of proteinuria and clinical parameters in IgAN were analyzed in the combined data from 2009 and 2010 (Tables 18, S2, S3).

With regard to the stages of CKD in patients with IgAN, stage 2 was predominant in the combined data from 2009 and 2010 (Table 18) and in both genders (Tables S2 and S3). The degree of proteinuria in the 24-h urine or spot urine samples increased with the progression of CKD stages in the combined data from 2009 and 2010 (Table 18) and in both genders (Tables S2 and S3). The systolic and diastolic blood pressure also increased with the progression of the CKD stage (Tables 18, S2, S3). Overall, 37.0 % of IgAN cases were being treated with anti-hypertensive agents and 4.6 % had diabetes mellitus (Table 18).

Cases in the J-KDR not reported in the J-RBR

In cases in the J-KDR not reported in the J-RBR, a clinical diagnosis of chronic nephritic syndrome was predominant in 2009, followed by hypertensive nephropathy, and a clinical diagnosis of renal disorder with metabolic disease (diabetic nephropathy) was predominant in 2010, followed

by nephrotic syndrome (Table 19). Polycystic kidney disease was detected in 2010 as a result of the secondary research studies performed on the basis of the J-KDR as described in the "Subjects and methods" section.

Secondary and longitudinal research by the J-RBR/J-KDR

Five of the secondary and longitudinal research studies, viz., the JNSCS, J-IDCS, J-IGACS, JRPGN-CS, and JDNCS, were started in 2009, and the J-PKD was started in 2010 in association with the J-RBR/J-KDR.

Discussion and comments

In 2009, the J-KDR started to register clinically-diagnosed cases without renal biopsies, in addition to cases with renal biopsies included in the J-RBR, which had been started in 2007. More than 80 % of the registered cases were in the J-RBR in 2009 and 2010, and thus the detailed data from the J-RBR and the clinical diagnosis alone for the J-KDR are described in this report.

Table 6 The frequency of pathological diagnoses as classified by pathogenesis in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies (n = 3,336)		Native kidneys (n = 3,165)	Total biopsies (n = 4,106)		Native kidneys (n = 3,869)	Total biopsies (n = 7,442)		Native kidneys (n = 7,034)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
IgA nephropathy	1,003	30.1	31.6	1,177	28.7	30.4	2,180	29.3	31.0
Primary glomerular disease (except IgA nephropathy)	862	25.8	27.2	1,090	26.5	28.1	1,952	26.2	27.7
Diabetic nephropathy	184	5.5	5.8	192	4.7	5.0	376	5.1	5.3
Renal graft	161	4.8	–	235	5.7	–	396	5.3	–
Lupus nephritis	137	4.1	4.3	220	5.4	5.7	357	4.8	5.1
MPO-ANCA positive nephritis	129	3.9	4.1	191	4.7	4.9	320	4.3	4.5
Hypertensive nephrosclerosis	123	3.7	3.9	157	3.8	4.1	280	3.8	4.0
Purpura nephritis	64	1.9	2.0	108	2.6	2.8	172	2.3	2.4
Amyloid nephropathy	45	1.3	1.4	58	1.4	1.5	103	1.4	1.5
Infection-related nephropathy	27	0.8	0.9	31	0.8	0.8	58	0.8	0.8
Thin basement membrane disease	26	0.8	0.8	39	1.0	1.0	65	0.9	0.9
PR3-ANCA positive nephritis	13	0.4	0.4	11	0.3	0.3	24	0.3	0.3
Alport syndrome	10	0.3	0.3	16	0.4	0.4	26	0.3	0.4
Thrombotic microangiopathy	9	0.3	0.3	8	0.2	0.2	17	0.2	0.2
Anti-GBM antibody-type nephritis	8	0.2	0.3	16	0.4	0.4	24	0.3	0.3
Others	535	16.0	16.7	557	13.6	13.6	1,092	14.7	15.4
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibody, PR3 proteinase 3, GBM glomerular basement membrane

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

The rates of primary glomerular disease (except IgAN) combined with that of IgAN in native renal biopsies were 59.3 %, 56.5 %, 58.8 %, and 58.5 % in 2007, 2008, 2009, and 2010 in the J-RBR. A recent report from a single center in Japan gave the rates as 77.8 % and 75.9 % between 1979 and 2008 and between 2004 and 2008, respectively [5]. In the present report for the J-RBR, the peak distribution of age was in the sixties in the combined data for 2009 and 2010. The difference in the rates of primary glomerular disease including IgAN may have been due to the higher mean ages of native biopsy cases in the J-RBR compared to the single center in this period (mean age, 46.7 vs. 40.8 years; age of the peak number, sixties vs. twenties), because the incidence of secondary glomerular disease increases in elderly patients, as reported previously [5].

IgAN is still the most frequently diagnosed disease in native kidney biopsies in Japan (33.0 %, 30.2 %, 31.6 %, and 30.4 % of cases in 2007, 2008, 2009, and 2010 in the J-RBR) [1, 4–6] similar to other Asian countries [7, 8] and some European countries [9, 10]. The peak distribution of age ranges was the twenties in 2009 and thirties in 2010. In patients with IgAN, the majority (68.1 %) of renal biopsies were performed in CKD stages G1 and G2, with median

proteinuria less than 1 g per day (Table 18), suggesting that there was a relatively early diagnosis of this biopsy-proven disease.

In the present clinical data, the degree of proteinuria increased with the progression of the CKD stage, and was more than 1 g per day for the median value in patients with CKD stages G4 and G5 (Tables 18, S1, S2). Previously, the best single predictor for renal deterioration was severe proteinuria on urine dipstick testing ($\geq$100 mg/dL), followed by hypoalbuminemia, mild hematuria, serum total protein levels, diastolic blood pressure, and histological grade, in a cohort study with 10 years follow-up from 1995 in Japan, the cohort of which exhibited a younger median age (27.7 years) and a peak distribution of age ranges in the teens [11, 12]. A recent report suggested that IgAN with nephrotic syndrome had a worse renal outcome compared to IgAN with non-nephrotic syndrome unless partial or complete remission was achieved [13]. Further studies are necessary to elucidate the risk factors or predictors for renal deterioration in IgAN in the present era utilizing the J-RBR, possibly as part of a new secondary clinical study.

MN was the most common histopathology in terms of primary glomerular disease other than IgAN in 2007

Table 7 The frequency of pathological diagnoses as classified by histopathology in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies (n = 3,336)		Native kidneys (n = 3,165)	Total biopsies (n = 4,106)		Native kidneys (n = 3,869)	Total biopsies (n = 7,442)		Native kidneys (n = 7,034)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
Mesangial proliferative glomerulonephritis	1,346	40.3	42.5	1,388	33.8	35.8	2,734	36.7	38.8
Membranous nephropathy	333	10.0	10.5	418	10.2	10.8	751	10.1	10.7
Minor glomerular abnormality	293	8.8	9.2	559	13.6	14.4	852	11.4	12.1
Crescentic and necrotizing glomerulonephritis	180	5.4	5.7	262	6.4	6.8	442	5.9	6.3
Focal segmental glomerulosclerosis	167	5.0	5.2	211	5.1	5.4	378	5.1	5.3
Nephrosclerosis	163	4.9	5.2	208	5.1	5.4	371	5.0	5.3
Renal graft	151	4.5	–	227	5.5	–	378	5.1	–
Membranoproliferative glomerulonephritis (types I and III)	85	2.5	2.7	97	2.4	2.5	182	2.4	2.6
Chronic interstitial nephritis	71	2.1	2.1	61	1.5	1.6	132	1.7	1.8
Sclerosing glomerulonephritis	63	1.9	2.0	44	1.1	1.1	107	1.4	1.5
Endocapillary proliferative glomerulonephritis	61	1.8	1.9	67	1.6	1.7	128	1.7	1.8
Acute interstitial nephritis	45	1.3	1.4	62	1.5	1.6	107	1.4	1.5
Acute tubular necrosis	9	0.3	0.3	10	0.2	0.2	19	0.3	0.2
Dense deposit disease	3	0.1	0.1	5	0.1	0.1	8	0.1	0.1
Others	366	11.0	11.3	487	11.9	12.5	853	11.5	12.0
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

Table 8 The frequency of pathological diagnoses as classified by histopathology in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Membranous nephropathy	259	30.1	330	30.3	589	30.2
Minor glomerular abnormalities	216	25.1	408	37.5	624	32.0
Mesangial proliferative glomerulonephritis	167	19.4	86	7.9	253	13.0
Focal segmental glomerulosclerosis	113	13.1	149	13.7	262	13.4
Membranoproliferative glomerulonephritis (types I and III)	48	5.6	51	4.7	99	5.1
Crescentic and necrotizing glomerulonephritis	19	2.2	18	1.7	37	1.9
Endocapillary proliferative glomerulonephritis	8	0.9	24	2.2	32	1.6
Chronic interstitial nephritis	7	0.8	3	0.3	10	0.5
Sclerosing glomerulonephritis	7	0.8	3	0.3	10	0.5
Nephrosclerosis	5	0.6	7	0.6	12	0.6
Acute interstitial nephritis	1	0.1	0	–	1	0.1
Acute tubular necrosis	0	–	1	0.1	1	0.1
Others	11	1.3	9	0.8	20	1.0
Total	861	100.0	1,089	100.0	1,950	100.0

Table 9 The frequency of pathological diagnoses as classified by pathogenesis in nephrotic syndrome in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Primary glomerular disease (except IgA nephropathy)	442	62.3	696	66.7	1,138	64.9
Diabetic nephropathy	85	12.0	78	7.5	163	9.3
IgA nephropathy	30	4.2	36	3.5	66	3.8
Lupus nephritis	30	4.2	58	5.6	88	5.0
Amyloid nephropathy	27	3.8	41	3.9	68	3.9
Infection-related nephropathy	6	0.8	7	0.7	13	0.7
Hypertensive nephrosclerosis	6	0.8	10	0.9	16	0.9
Purpura nephritis	4	0.6	8	0.8	12	0.7
Alport syndrome	3	0.4	0	–	3	0.2
Thrombotic microangiopathy	1	0.1	1	0.1	2	0.1
PR3-ANCA positive nephritis	1	0.1	0	–	1	0.1
MPO-ANCA positive nephritis	1	0.1	2	0.2	3	0.2
Others	74	10.4	106	10.2	180	10.3
Total	710	100.0	1,043	100.0	1,753	100.0

MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibody, PR3 proteinase 3

Table 10 The frequency of pathological diagnoses as classified by histopathology in primary glomerular disease except IgA nephropathy in nephrotic syndrome in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Membranous nephropathy	178	40.3	227	32.6	405	35.6
Minor glomerular abnormalities	172	38.9	348	50.0	520	45.7
Focal segmental glomerulosclerosis	47	10.6	82	11.8	129	11.3
Membranoproliferative glomerulonephritis (types I and III)	25	5.7	18	2.6	43	3.8
Mesangial proliferative glomerulonephritis	11	2.5	13	1.9	24	2.1
Crescentic and necrotizing glomerulonephritis	2	0.5	2	0.3	4	0.4
Sclerosing glomerulonephritis	2	0.5	0	–	2	0.2
Endocapillary proliferative glomerulonephritis	1	0.2	5	0.7	6	0.5
Others	4	0.9	1	0.1	5	0.4
Total	442	100.0	696	100.0	1,138	100.0

(31.4 %), 2008 (25.7 %), and 2009 (30.1 %) in the J-RBR and was also the most common type in primary nephrotic syndrome in 2007 (44.0 %) and 2009 (40.3 %) in the J-RBR. MN was also the most common primary cause of nephrotic syndrome in a northern European Caucasian population, with a biopsy rate of 4.5 per million population per year [14]. A total of 68.7 % and 68.8 % of primary MN cases exhibited nephrotic syndrome as the clinical diagnosis at the time of renal biopsy in 2009 and 2010 in the J-RBR. Yokoyama et al. recently reported in their clinical data analysis of 501 cases collected from the combined data of the J-RBR from 2007 to 2010 that nearly half of primary MN (49.1 %) cases showed a daily proteinuria of 3.5 g or higher [15]. The renal survival rate was 60 % at 20 years after diagnosis in patients with primary MN, and the renal survival rate in patients on steroid therapy was significantly higher in patients on supportive therapy alone in Japan [16], while spontaneous remission was reported to be common (32 %) in patients with primary MN with nephrotic syndrome in Spain [17], even in patients exhibiting chronic renal impairment [18]. Whether treatment with renin–angiotensin blockers or immunoglobulins other than steroids has a favorable effect on the renal prognosis of primary MN should be elucidated in future clinical studies.

The minor glomerular abnormalities in primary nephrotic syndrome, which correspond to MCNS, was the most common histopathology reported in 2008 (44.1 %) and 2010 (50.0 %) in the J-RBR. Since MCNS develops in patients at younger ages [5, 15] while primary MN develops in a relatively elderly population [15, 16], the frequency of these diseases may depend on the distribution of

Table 11 The frequency of clinical diagnoses in membranous nephropathy in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Nephrotic syndrome	178	68.7	227	68.8	405	68.8
Chronic nephritic syndrome	74	28.6	93	28.2	167	28.4
Recurrent or persistent hematuria	3	1.2	3	0.9	6	1.0
Renal disorder with collagen disease or vasculitis	1	0.4	1	0.3	2	0.3
Hypertensive nephropathy	1	0.4	0	–	1	0.2
Rapidly progressive nephritic syndrome	0	–	1	0.3	1	0.2
Renal disorder with metabolic disease	0	–	1	0.3	1	0.2
Acute nephritic syndrome	0	–	1	0.3	1	0.2
Acute renal failure	0	–	1	0.3	1	0.2
Others	2	0.8	2	0.6	4	0.7
Total	259	100.0	330	100.0	589	100.0

Table 12 The frequency of clinical diagnoses in minor glomerular abnormalities in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Nephrotic syndrome	172	79.6	348	85.3	520	83.3
Chronic nephritic syndrome	35	16.2	50	12.3	85	13.6
Recurrent or persistent hematuria	5	2.3	5	1.2	10	1.6
Acute renal failure	1	0.5	0	–	1	0.2
Rapidly progressive nephritic syndrome	1	0.5	1	0.2	2	0.3
Acute nephritic syndrome	1	0.5	1	0.2	2	0.3
Hypertensive nephropathy	0	–	1	0.2	1	0.2
Others	1	0.5	2	0.5	3	0.5
Total	216	100.0	408	100.0	624	100.0

the age ranges of patients registered in each year. Indeed, the rate of native biopsies of subjects younger than 20 years of age slightly increased from 11.4 % in 2009 to 12.7 % in 2010 (Table 3) and the mean age of patients with nephrotic syndrome slightly decreased from 53.5 years in 2009 to 50.1 years in 2010 (Table 5) in the J-RBR.

The average age of rapidly progressive nephritic syndrome was the highest (64.4 years) in the age distribution in the classification of clinical diagnosis in the J-RBR (Table 5). Elderly subjects (65 years and over) comprised nearly 25 % of cases, and very elderly subjects (80 years and over) comprised 2.5 % of the cases in the combined data for 2009 and 2010 in the J-RBR. It has been reported that there were statistically significant differences in the renal disease spectrum between elderly and younger subjects [19, 20]. The frequency of rapidly progressive nephritic syndrome in the clinical diagnosis dramatically increased from 4.0 % in the younger group (20–64 years)

to 19.6 % in the very elderly in the combined data from 2007 to November 2011 in the J-RBR [20]. A nationwide survey of rapidly progressive glomerulonephritis (RPGN) was conducted between 1989 and 2007 in Japan, and showed that 64.0 % of patients had pauci-immune-type RPGN, including 42.0 % renal-limited vasculitis, 19.4 % microscopic polyangiitis, and 2.6 % Wegener's granulomatosis (currently granulomatosis with polyangiitis) [21]. Since the frequency of myeloperoxidase–anti-neutrophil cytoplasmic antibody (MPO-ANCA)-positive nephritis has increased recently [22], a further subanalysis of rapidly progressive nephritic syndrome in the J-RBR should be performed to validate the recently published Japanese guidelines for RPGN [23].

Five new secondary research studies of the J-KDR were started in 2009, viz., the J-NSCS, J-IDCS, J-IGACS, J-RPGNCS, and J-DNCS, and the J-PKD was started in 2010. The J-RBR and J-KDR initiated two more clinical

Table 13 The frequency of clinical diagnoses in focal segmental glomerulosclerosis in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	*n*	%	*n*	%
Chronic nephritic syndrome	62	54.9	55	36.9	117	44.7
Nephrotic syndrome	47	41.6	82	55.0	129	49.2
Rapidly progressive nephritic syndrome	1	0.9	1	0.7	2	0.8
Renal disorder with metabolic disease	1	0.9	3	2.0	4	1.5
Recurrent or persistent hematuria	1	0.9	1	0.7	2	0.8
Hypertensive nephropathy	0	–	2	1.3	2	0.8
Acute nephritic syndrome	0	–	1	0.7	1	0.4
Inherited renal disease	0	–	1	0.7	1	0.4
Others	1	0.9	3	2.0	4	1.5
Total	113	100.0	149	100.0	262	100.0

Table 14 The profile of IgA nephropathy in native kidneys in J-RBR 2009 and 2010

IgA nephropathy	2009	2010	Total
Total native kidney biopsies (*n*)	1,001	1,176	2,177
Average age (years)	38.1 ± 17.2	39.3 ± 17.0	38.7 ± 17.1
Median age (years)	35 (24–52)	38 (26–53)	37 (25–52)
Male, *n* (%)	498 (49.8 %)[a]	585 (49.7 %)	1,083 (49.7 %)
Average age (years)	39.5 ± 18.2[b]	40.5 ± 18.4[b]	40.0 ± 18.3[b]
Median age (years)	38 (24–55)[b]	39 (25–56)	38 (24–56)[b]
Female, *n* (%)	503 (50.2 %)[a]	591 (50.3 %)	1,094 (50.3 %)
Average age	36.6 ± 15.9[b]	38.1 ± 15.4[b]	37.5 ± 15.7[b]
Median age	34 (24–49)[b]	37 (26–49)	36 (25–49)[b]

[a] Ratio indicates percentage of each gender in each biopsy category

[b] $P < 0.05$ compared to other gender

Table 15 Distribution of age ranges and gender in IgA nephropathy in J-RBR in 2009 and 2010

Age (years)	2009			2010			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
0–9	11	5	16	12	9	21	23	14	37
10–19	73	68	141	80	55	135	153	123	276
20–29	91	116	207	91	127	218	182	243	425
30–39	87	115	202	113	153	266	200	268	468
40–49	65	81	146	94	106	200	159	187	346
50–59	87	62	149	84	75	159	171	137	308
60–69	62	45	107	82	48	130	144	93	237
70–79	19	9	28	20	18	38	39	27	66
80+	3	2	5	9	0	9	12	2	14
Total	498	503	1,001	585	591	1,176	1,083	1,094	2,177
Under 20 (%)	16.9	14.5	15.7	15.7	10.8	13.3	16.3	12.5	14.4
65 and over (%)	9.4	5.2	7.3	11.5	5.4	8.4	10.5	5.3	7.9